QIAGEN N.V.

QGEN Healthcare Diagnostics & Research

QIAGEN N.V.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 5.65% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 7.94%, free cash flow grew 30.5% and total debt rose 13.8%, each against the same quarter a year earlier.

46.13 0.04 −0.09%
Market cap
$9.5B
P/E
23.6×
Fwd P/E
17.5×
Dividend yield
0.76%
F-score
8/9
Altman Z
3.81
Beneish M
−2.60
Dividend safety
66/100
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
79.51 170.50 38.84 0.00 31.93 23.25 25.09 27.50 117.80 22.30
Piotroski F-Score
4 6 7 3 7 7 5 4 5 8
P/S ratio
4.76 4.66 4.81 4.64 5.97 5.20 5.06 4.97 5.01 4.67
Altman Z-Score
3.23 2.61 2.39 2.31 3.25 3.53 3.67 3.84 4.00 3.81
Altman Z″-Score (non-manufacturers)
3.83 3.80 3.33 2.46 3.31 3.34 4.46 4.64 4.34 5.06
P/FCF ratio
25.70 40.71 34.58 126.64 72.68 27.09 19.14 32.91 19.74 21.84
Beneish M-Score
(2.79) (2.67) (2.62) (2.66) (2.52) (2.60) (2.81) (2.30) (2.89) (2.60)
P/Operating CF
63.66 86.93 65.32 64.76 41.38 59.03 87.12 64.51 51.76 51.92
Dividend Safety Score
— — — — — — — — — 66
P/B ratio
2.44 2.60 2.74 2.79 3.99 3.78 3.12 2.56 2.78 2.59
Price to Tangible BV
51.18 229.79 140.46 0.00 0.00 98.99 19.03 12.13 11.83 14.14
EV/Sales
5.16 5.18 5.26 5.19 6.61 5.59 5.26 5.20 5.13 5.18
EV/EBITDA
20.77 18.62 15.53 32.21 19.52 14.35 14.57 15.83 31.78 16.33
EV/Operating CF
20.21 25.62 21.96 23.96 27.02 19.71 15.76 22.24 15.07 16.54
EV/FCF
27.86 45.23 37.83 141.64 80.54 29.12 19.92 34.44 20.21 24.20
Quick Ratio
2.70 4.29 1.94 1.36 1.92 0.94 1.79 1.33 1.44 2.93
Current Ratio
3.36 5.07 2.22 1.65 2.84 1.39 2.46 1.99 1.88 3.90
Net Debt/EBITDA
1.62 1.88 1.33 3.41 1.91 1.00 0.57 0.70 0.75 0.84
Debt/Assets
24.89% 35.09% 37.82% 32.59% 32.76% 31.59% 29.60% 24.69% 24.46% 26.34%
Debt/Equity
0.41 0.70 0.83 0.67 0.69 0.63 0.54 0.40 0.39 0.44
Asset Turnover
0.32 0.30 0.28 0.28 0.34 0.37 0.34 0.32 0.34 0.35
Operating CF/Net income
4.25 7.10 1.89 (7.98) 1.27 1.25 1.69 1.35 8.06 1.54
Capex/Depreciation
(0.40) (0.52) (0.62) (1.01) (1.23) (0.84) (0.62) (0.69) (0.77) (1.05)
Interest Coverage
2.53 3.09 3.96 (0.35) 5.42 11.57 9.11 7.68 2.23 14.01
ROE
3.11% 1.57% 7.36% (1.60%) 13.47% 17.39% 12.90% 9.38% 2.27% 11.57%
ROA
1.89% 0.86% 3.53% (0.75%) 6.47% 8.53% 6.81% 5.50% 1.42% 7.10%
ROIC
1.96% 2.92% 5.03% (0.48%) 6.03% 9.91% 8.50% 6.01% 1.60% 6.72%
Return on Tangible Assets
6.90% 2.22% 11.23% (3.86%) 22.29% 41.66% 20.33% 18.62% 5.00% 17.65%
Average Days of Receivables
82.40 94.92 93.94 102.16 74.26 58.70 55.18 70.92 64.45 70.31
Research and Development Expense of Revenue
11.20% 10.87% 10.78% 10.31% 7.97% 8.44% 8.87% 10.10% 9.78% 8.97%
Selling, General and Administrative Expense of Revenue
41.62% 40.61% 33.08% 33.03% 28.09% 25.96% 28.20% 29.47% 28.53% 27.93%
Intangible Assets out of Total Assets
0.58 0.50 0.45 0.53 0.53 0.48 0.46 0.49 0.48 0.49
Share Based Compensation of Revenue
2.11% 2.43% 2.67% 4.32% 2.19% 1.71% 2.31% 2.40% 2.21% 2.41%
Graham Net Nets
(0.10) (0.13) (0.13) (0.16) (0.13) (0.08) (0.04) (0.02) (0.02) (0.05)
Graham Number
10.30 7.29 16.35 0.00 22.92 29.01 27.61 25.45 11.67 28.09
Earnings Yield
1.26% 0.59% 2.57% (0.64%) 3.13% 4.30% 3.99% 3.64% 0.85% 4.48%
Free Cash Flow Yield
3.89% 2.46% 2.89% 0.79% 1.38% 3.69% 5.23% 3.04% 5.07% 4.58%
Revenue per Share
6.36 6.94 7.40 7.51 9.14 11.02 10.19 9.07 8.89 9.62
Operating CF per Share
1.62 1.40 1.77 1.63 2.24 3.13 3.40 2.12 3.03 3.01
Capex per Share
(0.45) (0.61) (0.74) (1.35) (1.49) (1.01) (0.71) (0.75) (0.77) (0.95)
Free Cash Flow per Share
1.18 0.79 1.03 0.28 0.75 2.12 2.69 1.37 2.26 2.06
Cash per Share
2.53 5.01 7.37 4.27 3.50 5.22 6.75 4.88 5.18 5.06
Shareholders Equity per Share
12.39 12.44 12.98 12.49 13.67 15.16 16.49 17.57 16.02 17.39
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
12.39 12.44 12.98 12.49 13.67 15.16 16.49 17.57 16.02 17.39
Free Cash Flow
247.74 162.42 208.73 55.96 153.57 432.47 565.93 296.65 502.31 447.20
Working Capital
729.14 1,323.18 1,182.87 618.90 1,052.23 592.13 1,419.43 1,068.27 917.82 1,482.94
Capital Expenditures
(93.86) (124.36) (150.76) (274.88) (304.24) (206.53) (149.34) (162.80) (171.24) (207.13)
Net Current Asset Value
(663.53) (849.55) (958.30) (1,128.78) (1,447.37) (940.80) (427.17) (159.87) (162.43) (508.00)
EV/EBIT
69.85 47.88 29.62 0.00 32.01 19.98 21.21 24.92 103.90 23.23
Capex to Sales
0.07 0.09 0.10 0.18 0.16 0.09 0.07 0.08 0.09 0.10
Price to Operating Income
64.43 43.10 27.08 0.00 28.88 18.59 20.38 23.82 101.45 20.97
Other line items
Depreciation/Fixed assets
0.53 0.49 0.47 0.60 0.44 0.39 0.37 0.31 0.29 0.21
Cash ROIC
5.88% 3.05% 3.31% 1.10% 2.83% 7.09% 8.39% 4.65% 8.22% 6.85%
Accounts Receivable Turnover
4.44 4.23 3.98 3.75 4.63 6.06 6.24 5.57 5.41 5.56
Accounts Payable Turnover
9.53 8.97 7.79 6.76 6.28 7.30 7.57 8.00 12.08 10.14
Inventory Turnover
3.61 3.38 3.14 3.12 2.76 2.59 2.21 1.93 2.98 2.72
Average Days of Payables
37.89 43.66 50.58 59.37 67.63 46.14 47.61 41.98 30.07 33.55
Days of Inventory on Hand
101.03 114.98 118.71 119.55 166.68 149.28 172.61 198.75 100.83 139.39
Average Receivables
301.42 335.34 377.60 406.89 403.88 371.33 342.94 352.81 365.58 375.94
Average Payables
51.76 55.21 64.31 77.09 101.46 109.69 99.98 91.44 83.71 77.96
Average Inventory
136.57 146.24 159.42 166.81 230.94 309.35 342.74 378.17 338.82 290.57
Average Assets
4,243.66 4,673.36 5,393.42 5,491.97 5,552.62 6,008.29 6,217.34 6,201.46 5,902.41 5,985.43
Average Common Equity
2,587.58 2,574.05 2,587.98 2,585.78 2,667.22 2,947.19 3,281.58 3,637.19 3,687.55 3,672.75

Fold the line items

Columns are period end dates